Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




No Added Benefits for Full-Defrag Ablation for AF

By HospiMedica International staff writers
Posted on 30 Dec 2015
A stepwise approach to ablation for persistent atrial fibrillation (AF) does not offer any benefits over pulmonary vein isolation (PVI) alone, according to a new study.

Researchers at University Medical Center Hamburg-Eppendorf (UKE; Germany), University Hospital Cologne (Germany), and other institutions conducted a study involving 205 patients (151 men; mean age 61.7 years) who underwent de novo ablation for persistent AF. More...
Subsequently, the patients were prospectively randomized to either PVI alone (78 patients), or full defragmentation ablation (75 patients), consisting of PVI, ablation of complex fractionated electrograms, and additional linear ablation lines. The remaining 52 patients were not randomized due to AF termination with the original PVI.

The primary endpoint of the study was recurrence of any atrial tachycardia (AT) after a blanking period of three months. The results showed that during the entire study, 241 ablations were performed. At 12 months, the incidence of AT was similar between recipients of PVI alone and those who underwent full defragmentation (8.2% versus 8.5%, respectively). Arrhythmia-free survival rates were also similar between groups, at 63.9% with PVI only and 57.7% with full defragmentation.

The researchers also found, conversely, that despite the fact that the rate of major complications did not differ materially between groups, the full defragmentation arm suffered a 23.3% incidence of pericardial effusion with symptoms of pericarditis, compared with a much lower 5.3% incidence in their single-procedure counterparts. The study was published on December 22, 2015, in the Journal of the American College of Cardiology.

“Pulmonary vein isolation should be the initial strategy in patients with persistent AF undergoing catheter ablation, because more extensive ablation is associated with longer procedure duration, fluoroscopy, and radiofrequency exposure, without better rhythm control outcomes,” concluded lead author Julia Vogler, MD, of University Heart Center Hamburg, and colleagues. She added, however, that “pulmonary vein isolation alone appears to be insufficient for treating persistent AF, with disappointing long-term results.”

PVI is a catheter ablation technique developed to prevent focal triggers in the pulmonary veins from initiating episodes of AF. Although the procedure initially involved focal ablation with a catheter directly in the pulmonary veins, isolating the pulmonary veins by applying ablation energy at their junction with the left atrium is more effective. The PVI procedure is most suitable for patients whose recurring symptomatic episodes of AF have not been suppressed by anti-arrhythmic drugs, or who do not wish to take long-term anti-arrhythmic or anticoagulation medications.

Related Links:

University Medical Center Hamburg-Eppendorf
University Hospital Cologne



Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammography System (Analog)
MAM VENUS
Bipolar Coagulation Generator
Aesculap
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.